Marmoset
Core
The drugs that pass the Mouse Core then land on the TRIDENT Marmoset Core - the final stage in neurotherapeutic validation. The TRIDENT Marmoset Core is currently developing marmoset disease models that can faithfully recapitulate complex human brain disorders, thereby providing a powerful model not only to study the pathophysiology of neurodegenerative diseases but also to test the efficacy of neurotherapeutics in a model that is a close relative to humans. Drugs that pass this final stage of the TRIDENT platform are regarded as robustly de-risked and will have a near guarantee of success in clinical trials.
The TRIDENT Marmoset Core is proficient in generating developmental and disease models of non-human primates , specifically marmosets. Further, using their extensive expertise in brain imaging and neurophysiological approaches, they are uniquely poised to uncover how the central and peripheral nervous systems become dysfunctional in disease, using an animal model that is phylogenetically proximal, neuroanatomically, and genetically similar to humans.
TRIDENT is committed to the highest standards of care for animals in research.
Current Models
α-synucleinopathy
MEET THE TEAM
DR. JUSTINE CLERY
TRIDENT Co-Principal Investigator
and Marmoset Team Lead
Assistant Professor, Department of Neurology and Neurosurgery,
McGill University
Head of the Sensory and Social Brain Mechanisms (SSBM) Lab at The Neuro,
McGill University
Email:
​​
Website:
https://www.mcgill.ca/neuro/justine-clery-phd​​
DR. STEFAN EVERLING
TRIDENT Co-Principal Investigator
and Marmoset Team Lead
Professor of Physiology and Pharmacology, Western University
Scientist at the Robarts Research Institute at the University of Western Ontario.
Email:
​​Website:
http://www.everling-lab.org/stefan-everling.html
​
DR. RAVI MENON
TRIDENT Principal Investigator
and Imaging Biomarker Team Lead
Professor, Departments of Medical Biophysics, Medical Imaging, Neuroscience, and Psychiatry, Western University
Canada Research Chair in Functional and Molecular Imaging
Research Scientist, CFMM
Co-Scientific Director of BrainsCAN
​Email:
​​
Website:
https://cfmm.uwo.ca/people/core_scientists/ravi_menon.html
DR. MARCO PRADO
TRIDENT Co-Principal Investigator
and Molecular Biomarker Team Lead
Professor, Department of Physiology and
Pharmacology and Department of Anatomy
& Cell Biology
Scientist, Robarts Research Institute
Canada Research Chair in Neurochemistry
of Dementia
Deputy Editor in Chief Journal of Neurochemistry
Email:
​Website:
https://www.schulich.uwo.ca/physpharm//people/faculty/prado_marco.html
​
​